

CURRICULUM VITAE	
Nome e Cognome SILVIA DEAGLIO, M.D., Ph.D.	Attuale posizione lavorativa Professore ordinario di Genetica Medica Università di Torino Direttore SC Immunogenetica e Biologia dei Trapianti, AOU Città della Salute e della Scienza di Torino

ISTRUZIONE/FORMAZIONE			
ISTITUZIONE	DIPLOMA	ANNI	AMBITO DI STUDIO
Università di Torino	Laurea	1992-1998	Medicina e Chirurgia
Università di Torino	Specializzazione	1998-2002	Oncologia
Università di Torino	Dottorato di ricerca	2002-2006	Genetica
The European Board of Surgery	Fellow of the Board of surgery in Transplant Immunology	2021	Immunogenetica dei trapianti

(URL for web site: <http://www.dsm.unito.it/persona/silvia.deaglio>); ORCID ID: 0000-0003-0632-5036)

Dichiarazione personale

Ho conseguito la laurea in medicina e la specializzazione in oncologia presso l'Università di Torino. Nel 2002 ho iniziato il Dottorato di ricerca in Genetica sempre presso l'Università di Torino, trascorrendo un periodo di ricerca presso l'Unità di Immunologia dei Trapianti del **Beth Israel Deaconess Medical Center** dell'Università di Harvard sotto la supervisione del Dr. Simon Robson e Dr. Terry Strom. Durante quel periodo ho contribuito all'identificazione della generazione di adenosina come meccanismo fondamentale di soppressione della risposta immunitaria da parte delle cellule T regolatorie. Dopo essere tornata in Italia alla fine del 2005 come **Ricercatore Universitario** di genetica, ho ottenuto i miei primi due finanziamenti da "principal investigator", incentrati sulla caratterizzazione genetica delle interazioni tumore-ospite nel modello malattia della leucemia linfatica cronica. Dal 2010 al 2019 sono stata Principal Investigator dell'Unità di immunogenetica della Human Genetics Foundation a Torino (ora **Italian Institute for Genomic Medicine, IIGM**, <https://www.iigm.it/site/>). Dalla fine del 2011 al luglio 2022 sono stata **Professore Associato di Genetica Medica all'Università di Torino**. Tra il 2010 e il 2014 ho collaborato con i gruppi di ricerca del Prof Dalla Favera (Columbia University, NY) e del Prof Gaidano (Università del Piemonte Orientale) nella definizione dell'organizzazione genomica della leucemia linfatica cronica e del linfoma splenico marginale, e delle implicazioni funzionali delle mutazioni somatiche identificate. Inoltre, abbiamo identificato alcuni elementi genetici germinali associati allo sviluppo della leucemia linfatica cronica e della sindrome di Richter. Dal 2014 al 2016, sono stata **Professore associato in visita presso il Weill Cornell Medicine**, per creare modelli preclinici di xenotrapianto di pazienti con CLL e sindrome di Richter. Questi modelli sono stati successivamente usati per determinare l'effetto di nuovi farmaci. Da settembre 2016 sono entrata a far parte del Servizio di Immunogenetica e Biologia dei Trapianti **dell'Ospedale Universitario Città della Salute e della Scienza di Torino** in qualità di dirigente medico e dal 1/11/2023 di **Direttore**.

I miei interessi scientifici si concentrano sull'identificazione di nuovi determinanti genetici che influenzano il rigetto degli organi e sulla **identificazione di marcatori di rigetto**. In particolare, abbiamo recentemente brevettato un sistema per monitorare **la percentuale di DNA libero circolante di origine del donatore nella circolazione del ricevente che sfrutta i polimorfismi HLA al locus DRB1 e DQB1**. Inoltre, il Servizio fornisce **diagnosi e consulenza genetica ai pazienti che necessitano di trapianto di organi con sospetta malattia monogenica**.

Esperienze professionali

- 1993-1998: Studente frequentatore, Laboratorio di Biologia cellulare, Dipartimento di Genetica, Biologia e Biochimica, Università di Torino.
- 1999-2002: Specializzando in Oncologia, Divisione di oncologia, Ospedale Molinette, Torino.
- 2002-2004: Medico frequentatore, Breast Unit, Divisione di oncologia, Ospedale Molinette, Torino.
- 2002-2006: Dottorato di ricerca (Genetica), Laboratorio di Immunogenetica, Dipartimento di Genetica, Biologia e Biochimica, Università di Torino.
- 2004-2005: Instructor in Medicine e (2005) Visiting Assistant Professor, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (Reference: Simon Robson and Terry Strom).
- 2005-2011: Ricercatore in Genetica medica, "Confermato" dall'1 Gennaio 2008, Università di Torino
- 2010-2019: Ricercatore Principale, Unità di Immunogenetica dell'Italian Institute for Genomic Medicine (ex Human Genetics Foundation), Torino
- 2011-2022: Professore Associato in Genetica Medica, Università di Torino, Torino, Italia [con abilitazione a professore di I fascia da Gennaio 2014].
- 2014-2016: Visiting Associate Professor, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, Cornell University, New York, NY.
- 2016-: Visiting scientist, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY.
- 2016-2023: Dirigente medico, Servizio di Immunogenetica e Biologia dei Trapianti, Ospedale Universitario Città della Salute e della Scienza, Torino.
- Luglio 2022-: **Professore Ordinario di Genetica Medica, Università di Torino.**
- 1/11/2023-: **Direttore Scuola di Specializzazione in Genetica Medica per non medici**
- 1/11/2023-: **Direttore, Servizio di Immunogenetica e Biologia dei Trapianti, Ospedale Universitario Città della Salute e della Scienza, Torino.**
- 1/1/2024-: **Second Opinion nazionale per il Centro Nazionale Trapianti (Ministero della Salute) per le malattie rare nei potenziali donatori d'organo** **Periodi di ricerca all'estero**
- Maggio 2003: Department of Hematology, Essen University (Essen, Germany)
 - Maggio 2004-Novembre 2005: Beth Israel Deaconess Medical Center, Harvard University (Boston, MA)
 - Marzo 2007: The Feinstein Institute for Medical Research (Manhasset, NY)
 - Settembre 2014-Agosto 2016: Weill Cornell Medicine (New York, NY)

Attività didattica

1) Docente titolare dei seguenti insegnamenti presso corsi di laurea dell'Università di Torino:

- Corso di Genetica Umana, corso di Laurea in Medicina e Chirurgia (I anno, circa 150 studenti, dal 2011)
- Corso di Genetica Medica, corso di Laurea in Medicina e Chirurgia (V anno, circa 150 studenti, dal 2024)
- Corso di Genetica Medica, corso di laurea in Infermieristica (III anno, 2 canali dal 2005)
- Corso di Genetica Medica, corso di laurea in Infermieristica pediatrica (II anno, circa 25 studenti, dal 2011)
- Corso di Genetica Medica, corso di laurea in tecnici di laboratorio (III anno, circa 50 studenti, dal 2020)

2) Membro del collegio docenti del Dottorato di Scienze Biomediche e Oncologia Umana (dal 2005 al 2023) e del collegio docenti del Dottorato di Fisiopatologia Medica (dal 2024).

- Coordinatrice dell'indirizzo di Immunodiagnostica (dal 2018 al 2023).

3) Docente titolare dei seguenti insegnamenti presso le seguenti scuole di specializzazione dell'Università di Torino:

- Scuola di specializzazione in genetica medica: corso di Immunogenetica
- Scuola di specializzazione in genetica medica: corso di Genetica delle Malattie Renali

- Scuola di specializzazione in ematologia: corso di Immunogenetica
- Scuola di specializzazione in gastroenterologia: corso di Genetica Medica

4) Attività di tutoraggio per:

- studenti di Dottorato (dal 2005, 14 PhD formati)
- studenti della scuola di specializzazione in genetica medica (medici e non medici, dal 2016)
- studenti di medicina e biotecnologie ai fini della laurea magistrale (circa 3-4 studenti/anno, dal 2005) - studenti del programma MD/PhD

Responsabilità istituzionali

- 2018-2023 Coordinatore del curriculum in Immunodiagnostica, scuola di Dottorato in Scienze Biomediche ed Oncologia Umana, Università di Torino
- 2018- Membro della Commissione Ricerca del Dipartimento di Scienze Mediche
- 2018-2022 Membro del comitato scientifico del Progetto di Eccellenza del Dipartimento di Scienze Mediche
- 2018- Coordinatore della Biobanca del Dipartimento di Scienze Mediche (http://www.progettoeccellenzateseo.unito.it/it/biobank_personel)
- 2021- Referente dipartimentale per le questioni relative al GDPR sulla privacy
- 2022- Membro della Giunta del Dipartimento di Scienze Mediche
- 2024- Membro della Commissione Brevetti dell'Università di Torino

Attività assistenziale

Dirigente medico convenzionato presso la SC Immunogenetica e Biologia dei Trapianti dell'AOU Città della Salute e della Scienza di Torino a partire dal 2016, dove ha svolto le seguenti attività assistenziali:

- 2017- reperibilità per test di immunogenetica e istocompatibilità per i trapianti di organo
- 2017- consulenze di immunogenetica pre-test e post-test per malattie associate HLA (indicativamente 150-200/anno)
- 2018- responsabile della sezione Malattie Monogeniche suscettibili di trapianto (<https://www.trapiantipiemonte.it/immunogenetica/>).
- 2018- refertazione di test genetici di sequenziamento di esoma clinico (Illumina True Sight Once) e di pannelli specifici (Illumina True Sight cardio). Nel 2022 circa 500 esomi clinici e circa 400 *pannelli cardio*
- refertazione di test di conferma mediante Sanger o MLPA. Nel 2022 circa 850 conferme Sanger e circa 80 conferme MLPA
- 2019- consulenze di genetica medica pre- e post-test per malattie genetiche suscettibili di trapianto (quante). Nel 2022 circa 900 pre-test e circa 800 post-test
- 2020- vicedirettore del laboratorio HLA certificato EFI
- 2022- Incarico di alta specializzazione C2
- 2024- Incarico di Direzione di Struttura Complessa

Attività scientifica:

1) Pubblicazioni (aggiornato al 21-8-2024):

Autore di 216 pubblicazioni in PubMed

<https://pubmed-ncbi-nlm-nih-gov.bibliopass.unito.it/?term=deaglio>

First/last/corresponding author publications: 91 (42%) H-index:

63 (Scopus) Total citations: 13823

L'elenco delle pubblicazioni è al fondo del CV.

2) Associazioni professionali

- 2003-: American Association for Cancer Research (full member)
- 2004-: American Association of Immunologists (full member)
- 2008-: Italian Society for Experimental Hematology (full member)
- 2008-: American Society of Hematology (full member)
- 2009-: Member of the European Research Initiative on CLL (ERIC)

- 2012-: Member of the Henry Kunkel Society
- 2015-: Member of the European Federation of Immunogenetics (EFI)
- 2016-: Member of the Italian Society of Human Genetics (SIGU)
- 2018-: Member of the Italian Society of Transplant Biology (AIBT)

3) Revisore e attività editoriale per:

Revisore per i seguenti giornali:

- Nature Communications, Blood, Leukemia, Cancer Research, Clinical Cancer Research, The Journal of Immunology, Haematologica, Molecular Medicine, Leukemia and Lymphoma, Leukemia Research, Expert Reviews in Hematology, Experimental Cell Research, European Journal of Haematology, Purinergic Signaling, Journal of Transplantation, Journal of Cancer Research and Clinical Oncology, International Journal of Molecular Sciences, Human Immunology.

Revisore di progetti per:

- AERES, Cancer Research UK, Irish Health Research Board, European Hematology Association, Swiss National Science Foundation, Leukaemia & Lymphoma Research, Italian Ministry of Education, National Science Center of Poland, Health Research Council of New Zealand.

Membro redazione editoriale di:

- "Blood"
- Open Medicine Journal (<http://degruyteropen.com/people/sdeaglio/>); - "Cancers" (<https://www.mdpi.com/journal/cancers/editors>).
- "International Journal of Cancer Immunology and Immunotherapy";
- Journal of Immunology and Immunotherapy (<https://www.imedpub.com/journal-immunologyimmunotherapy/editors.php>)
- "Current Signal Transduction Therapy" (<http://www.bentham.org/cstt/EBM.htm>);
- "American Journal of Cancer Research" (<http://www.ajcr.us/EditorialBoard.html>);
- "Journal of Cancer Therapeutics and Research" (<http://www.hoajonline.com/Journal-of-CancerTherapeutics-and-Research.html#tabs2-2>);
- "World Journal of Translational Medicine" (<http://www.wjgnet.com/2220-6132office/>);
- "World Journal of Biological Chemistry" (<http://www.wjgnet.com/1949-8454/edboard.htm>);

4) Premi e riconoscimenti

- 1996: PBI international Prize for the best abstract presented at the 1996 Immunology Cooperation Group (GCI) meeting in L'Aquila, Italy.
- 1998: Telethon Foundation Prize for scientific research, Roma, Italy.
- 1999: Optime Prize for best qualified students, Industrial Association of Torino. Torino, Italy.
- 2002: Cecilia Cioffrese prize for cancer research (Milano, Italy)
- 2004: Walter Knapp Young Investigator Award. Prize presented at the VIII HLDA Congress, December 10-14, 2004, Adelaide, Australia.

2006: Italian Cancer League Prize for translational researches in hematology (Asti, October 18, 2006)

5) Organizzazione di meeting scientifici

- Membro del Comitato Scientifico del meeting “CD38 ectoenzyme family” meeting, Torino, giugno 2006
- Revisore degli abstract e moderator, 57^{mo} e 58^{mo} meeting annual della American Society of Hematology (2015, 2016)
- Membro del Comitato Scientifico del “Keystone Symposium on purinergic signalling” (Vancouver, 2016)
- Membro del Comitato Scientifico del 17^{mo} International Workshop on CLL (New York, June 2017)

6) Presentazioni e seminari selezionati (2016-2024) 2018

- Speaker, International Symposium on CHRONIC LYMPHOCYTIC LEUKEMIA: ADVANCES IN PATHOGENESIS AND TREATMENT. Venice, March 2018
- Speaker, Cancer Cluster Salzburg Conference, Salzburg April 2018
- Speaker, ASH Lymphoma Biology Meeting, Washington, August 2-5, 2018
- Speaker, ERIC International Meeting “New Frontiers in CLL Research”, Barcelona October 2018

2019

- Seminario, Lymphoma Biology Series, Cambridge University (Host. Dr. I Ringshausen)
- Speaker, iwCLL meeting, Edinburg, UK, Sept 20-23 2019
- Speaker, 5th ESH Conference on lymphoid malignancies, Estoril, Portugal, Oct 2-5, 2019
- Speaker, Lymphoma and Myeloma Conference, New York, October 23-26, 2019

2020

- Speaker, First Translational Research Conference on Chronic Lymphocytic Leukemia (Paris, November 2020)
- Abstract reviewer for the American Society of Hematology 62nd Annual Meeting (online event only)

2021

- Speaker, Meeting annual della Society for Hematological Oncology (SOHO), Houston, September 8-11, 2021)
- Speaker, 24th meeting Patologia Immune e Malattie Orfane (Turin, September 13-15, 2021)
- Speaker, Technology Forum Life Sciences, Osservatorio sulla Genomica: confronto con best practice internazionali, approccio di cura al paziente e tema etico. (September 30, 2021, evento online)
- Speaker, annual meeting della Società Italiana Trapianto Organi (SITO), Napoli 3 October 3-5, 2021
- Speaker at the international course “Training on strategies to foster solutions of undiagnosed RD cases”, October 27-29 2021 (online event)
- Speaker, 63rd American Society of Hematology Meeting, Atlanta, GA, December 11-14, 2021.

Speaker at the online course on undiagnosed diseases organized by the Istituto Superiore di Sanità, April 19-21, 2022

- Speaker, annual meeting della Società Italiana Trapianto Organi (SITO), Trieste 3 October 3-5, 2022
- Speaker at the meeting “Il nuovo ponte sulla leucemia linfatica cronica per unire ricerca e clinica”, Genoa November 25-26, 2022

Speaker at the UK CLL forum, London, March 8, 2023

- Speaker at the “corso di aggiornamento “Gestione Clinica del Trapianto renale”, Torino, 13-14 maggio, 2023
- Speaker at The Sixth International Renal Meeting with Mayo Clinic in Sardinia, May 29-June 2, 2023
- Speaker at the Congress of the “Società Italiana di Nefrologia” annual meeting, Turin Oct 4-7, 2023
- Member of the organizing committee, session chair and speaker at the XX iwCLL meeting, Octo 6-9, Boston, MA.

- Speaker at the European School of Hematology Meeting on Lymphoid malignancies, Estoril, Portugal Oct 20-22, 2023.

2024

- Speaker at the European Hematology Association, Madrid, Spain, June 14-16 2024
- Speaker at the Cambridge Lymphoma Biology International Symposium, Cambridge, UK, Sept 17-18, 2024
- Speaker at the ERIC Meeting in Barcelona, September 26-28, 2024

7) Finanziamenti

Attivi

Title	Project code	Funding agency	Duration	Amount (euros)	Role
A ménage à trois involving the B cell receptor, NOTCH1 and NAMPT: therapeutic implications for CLL and RS patients	IG23095	AIRC	2020-2024	660.000 (approx 130.000 / year)	PI
Cell free DNA profiling as a tool to monitor clinically-relevant events in allogeneic hematopoietic stem cell transplantation	Prot. P2022ZRF5H	Mur – PRIN project	2 years	160.000	PI
Leukemic Cell And Microenvironment Interactions as the Culprit of Chronicity in CLL	PNRR-MAD-20221237644	Ministero della Salute	2 anni 2023-2025	200.000	PI of operative unit
Exploring the molecular landscape of pediatric idiopathic nephrotic syndrome associated glomerular damage and proteinuria.	PRIN2022-2022B9WC3F	Miur – PRIN project	2 years	81000	PI of operative unit
Cell free DNA profiling as a tool to monitor clinically-relevant events in allogeneic hematopoietic stem cell transplantation	PRIN-PNRR-2022 P2022ZRF5H	Miur – PRIN project	2 years	160000	PI

Principali finanziamenti conclusi

Title	Project code	Funding agency	Duration	Amount	Role
Traguardi di eccellenza nelle scienze mediche esplorando le omiche	Progetto strategico di Eccellenza Dipartimentale D15D18000410001	Miur – Dipartimenti di Eccellenza	5 years, start date 01-01-2018	400.000 (approx 80.000 / year)	PI of operative unit (area trapianti)
Traguardi di eccellenza nelle scienze mediche esplorando le omiche	Progetto strategico di Eccellenza Dipartimentale D15D18000410001	Miur – Dipartimenti di Eccellenza	5 years, start date 01-01-2018	265.000 (approx 53.000 / year)	PI of operative unit (biobank)
Understanding and targeting the extracellular NADome in inflammation	PRIN2017CBNCYT_002	Miur – PRIN project	3 years	155.000	PI of operative unit
Monitoraggio Rigetto Acuto Trapianto d'Organo (MiRATO)	Progetto PoC (proof of concept)	Fondazione Links	01-04-2022	50,000	PI

Meccanismi molecolari e cellulari nella progressione della leucemia linfatica cronica: nuovi approcci terapeutici	Ricerca finalizzata Bando 2009	Regione Piemonte	2009	20,000	PI
Combined role of CD38 and ZAP70 in CLL: from pathogenesis to diagnosis, prognosis and therapy	IG4169	AIRC	2006-2008	150,000	PI of operative unit
Nucleotide-metabolizing enzymes in the maintenance and progression of CLL: potential therapeutic applications?	IG8590	AIRC	2009-2011	225,000	PI
Cooperation between adenosinergic and hypoxic signals in the organization of the leukemic niche	IG12754	AIRC	2012-2015	290,000	PI
L'espressione coordinata degli enzimi CD39 e CD73 da parte di cellule di leucemia linfatica cronica contribuisce a indurre immunosoppressione e a creare condizioni microambientali favorevoli alla crescita	PRIN2009 2009LMEEEH_002	Ministero dell'Università	2011-2014	89,000	PI of operative unit
DECYPHERING THE MOLECULAR BASIS OF SPLENIC MARGINAL ZONE LYMPHOMA BY WHOLE EXOME SEQUENCING AND FUNCTIONAL GENOMICS		Cariplo	2013-2015	290,000 (two units)	PI of operative unit
Fattori solubili, recettori di membrana e controllo genetico nelle interazioni tumore/ospite	Futuro in ricerca RBFR08ATLH	Ministero dell'Università	2010-2014	482,000	PI
Identificazione e caratterizzazione funzionale di nuove lesioni genetiche nelle neoplasie linfoidi	Futuro in ricerca RBFR12D1CB_002	Ministero dell'Università	2013-2016	300,000	PI of operative unit
Identification of novel prognostic factors and therapeutic targets for Richter's syndrome	Progetto giovani ricercatori GR-2008-1138053	Ministero della Salute	2010-2013	533,000	PI (primo progetto classificato)
NEW GENETIC LESIONS CHARACTERIZING HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND FUNCTIONAL IMPLICATIONS	Giovani Ricercatori GR-2010-2317594	Ministero della Salute	2013-2015	110,000	PI of operative unit

Mechanisms of action of adenosine deaminase in cancer cells		Halozyme	2016-2018	90,000	PI
Pleiotropic transcriptional control mechanisms of CD49d expression in trisomy 12 chronic lymphocytic leukemia: implications for novel therapeutic approaches	GR-2011-02346826	Ministero della Salute	2015-2018	129,000	PI of operative unit
Understanding tumor-host interactions and therapy resistance in chronic lymphocytic leukemia: moving up a NOTCH?	IG17314	AIRC	2016-2018	319,000 euros	PI

8) **Brevetti**

- Brevetto nazionale ed europeo “Immunological method and kit for in vitro diagnosis of tumour and/or inflammatory conditions”, codice PCT/IB2019/051314, di cui sono inventrici: Prof Silvia Deaglio e Dott Valentina Audrito.
- Brevetto nazionale ed europeo “*Diagnosi non invasiva del rigetto acuto nel trapianto di organo solido*”. Codice P2021/10, di cui sono inventrici: Prof Silvia Deaglio, Prof Tiziana Vaisitti, Dott Monica Sorbini

9) **Elenco delle pubblicazioni**

1. Deaglio S, Dianzani U, Horenstein AL, Fernandez JE, van Kooten C, Bragardo M, Funaro A, Garbarino G, Di Virgilio F, Banchereau J, Malavasi F: Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. *J Immunol* 156:727-34, 1996
2. Cesano A, Visonneau S, Deaglio S, Malavasi F, Santoli D: Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells. *J Immunol* 160:1106-15, 1998
3. Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, Dianzani U, Stockinger H, Malavasi F: Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. *J Immunol* 160:395-402, 1998
4. Fernandez JE, Deaglio S, Donati D, Beusan IS, Corno F, Aranega A, Forni M, Falini B, Malavasi F: Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. *J Biol Regul Homeost Agents* 12:81-91, 1998
5. Baj G, Arnulfo A, Deaglio S, Tibaldi E, Surico N, Malavasi F: All-trans retinoic acid inhibits the growth of breast cancer cells by up-regulating ICAM-1 expression. *J Biol Regul Homeost Agents* 13:115-22, 1999
6. Vallario A, Chilosi M, Adami F, Montagna L, Deaglio S, Malavasi F, Caligaris-Cappio F: Human myeloma cells express the CD38 ligand CD31. *Br J Haematol* 105:441-4, 1999
7. Ausiello CM, Urbani F, Lande R, la Sala A, Di Carlo B, Baj G, Surico N, Hilgers J, Deaglio S, Funaro A, Malavasi F: Functional topography of discrete domains of human CD38. *Tissue Antigens* 56:53947, 2000

8. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, Rosa M, Giana M, Villa L, Malavasi F, Surico N: Retinoids in breast cancer prevention and treatment. A review of the literature. *Eur J Gynaecol Oncol* 21:411-5, 2000
9. Cassoni P, Fulcheri E, Carcangiu ML, Stella A, Deaglio S, Bussolati G: Oxytocin receptors in human adenocarcinomas of the endometrium: presence and biological significance. *J Pathol* 190:470-7, 2000
10. Deaglio S, Mallone R, Baj G, Arnulfo A, Surico N, Dianzani U, Mehta K, Malavasi F: CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. *Chem Immunol* 75:99-120, 2000
11. Zilber MT, Gregory S, Mallone R, Deaglio S, Malavasi F, Charron D, Gelin C: CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation. *Proc Natl Acad Sci U S A* 97:2840-5, 2000
12. Cassoni P, Marrocco T, Deaglio S, Sapino A, Bussolati G: Biological relevance of oxytocin and oxytocin receptors in cancer cells and primary tumors. *Ann Oncol* 12 Suppl 2:S37-9, 2001
13. Cassoni P, Sapino A, Munaron L, Deaglio S, Chini B, Graziani A, Ahmed A, Bussolati G: Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. *Endocrinology* 142:1130-6, 2001
14. Deaglio S, Canella D, Baj G, Arnulfo A, Waxman S, Malavasi F: Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As₂O₃) on myeloma cells. *Leuk Res* 25:227-35, 2001
15. Deaglio S, Mallone R, Baj G, Donati D, Giraudo G, Corno F, Bruzzone S, Geuna M, Ausiello C, Malavasi F: Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway. *FASEB J* 15:580-2, 2001
16. Deaglio S, Mehta K, Malavasi F: Human CD38: a (r)evolutionary story of enzymes and receptors. *Leuk Res* 25:1-12, 2001
17. Morabito F, Mangiola M, Oliva B, Stelitano C, Callea V, Deaglio S, Iacopino P, Brugiattelli M, Malavasi F: Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. *Leuk Res* 25:927-32, 2001
18. Musso T, Deaglio S, Franco L, Calosso L, Badolato R, Garbarino G, Dianzani U, Malavasi F: CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. *J Leukoc Biol* 69:605-12, 2001
19. Sapino A, Bongiovanni M, Cassoni P, Righi L, Arisio R, Deaglio S, Malavasi F: Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast. *J Pathol* 194:254-61, 2001
20. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E: Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. *Breast Cancer Res Treat* 73:61-73, 2002
21. Cassoni P, Sapino A, Deaglio S, Bussolati B, Volante M, Munaron L, Albin A, Torrisi A, Bussolati G: Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. *Cancer Res* 62:2406-13, 2002

22. Deaglio S, Capobianco A, Cali A, Bellora F, Alberti F, Righi L, Sapino A, Camaschella C, Malavasi F: Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. *Blood* 100:3782-9, 2002
23. Deaglio S, Zubiaur M, Gregorini A, Bottarel F, Ausiello CM, Dianzani U, Sancho J, Malavasi F: Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. *Blood* 99:2490-8, 2002
24. Gregorini A, Cinti C, Pigliapoco F, Deaglio S, Ferrero E, Papa S, Palma F: Rapid and sensitive detection of recombinant soluble proteins in the supernatant of transfected mammalian cells. *J Biol Regul Homeost Agents* 16:93-7, 2002
25. Lande R, Urbani F, Di Carlo B, Sconocchia G, Deaglio S, Funaro A, Malavasi F, Ausiello CM: CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes. *Cell Immunol* 220:30-8, 2002
26. Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, Malavasi F: Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil. *Haematologica* 87:217-8, 2002
27. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U, Malavasi F: CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. *Blood* 102:2146-55, 2003
28. Durig J, Nuckel H, Huttmann A, Kruse E, Holter T, Halfmeyer K, Fuhrer A, Rudolph R, Kalhori N, Nusch A, Deaglio S, Malavasi F, Moroy T, Klein-Hitpass L, Duhrsen U: Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. *Blood* 101:2748-55, 2003
29. Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, Malavasi F: Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome? *Haematologica* 88:354-5, 2003
30. Righi L, Deaglio S, Pecchioni C, Gregorini A, Horenstein AL, Bussolati G, Sapino A, Malavasi F: Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. *Am J Pathol* 162:1163-74, 2003
31. Savarino A, Bensi T, Chiocchetti A, Bottarel F, Mesturini R, Ferrero E, Calosso L, Deaglio S, Ortolan E, Butto S, Cafaro A, Katada T, Ensoli B, Malavasi F, Dianzani U: Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. *FASEB J* 17:461-3, 2003
32. Tenca C, Merlo A, Zarccone D, Saverino D, Bruno S, De Santanna A, Ramarli D, Fabbi M, Pesce C, Deaglio S, Ciccone E, Malavasi F, Grossi CE: Death of T cell precursors in the human thymus: a role for CD38. *Int Immunol* 15:1105-16, 2003
33. Calzolari A, Deaglio S, Sposi NM, Petrucci E, Morsilli O, Gabbianelli M, Malavasi F, Peschle C, Testa U: Transferrin receptor 2 protein is not expressed in normal erythroid cells. *Biochem J* 381:629-34, 2004
34. Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L, Boumsell L, Malavasi F: CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. *Blood* 105:3042-50, 2005
35. Isoardo G, Deaglio S, Cocito D, Migliaretti G, Ferrero E, Cavallo F, Durelli L, Malavasi F: Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells. *J Neuroimmunol* 161:78-86, 2005

36. Vaisitti T, Deaglio S, Malavasi F: Cationization of monoclonal antibodies: another step towards the "magic bullet"? *J Biol Regul Homeost Agents* 19:105-12, 2005
37. Calzolari A, Raggi C, Deaglio S, Sposi NM, Stafsnes M, Fecchi K, Parolini I, Malavasi F, Peschle C, Sargiacomo M, Testa U: Tfr2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. *J Cell Sci* 119:4486-98, 2006
38. Deaglio S, Malavasi F: The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes. *Purinergic Signal* 2:431-41, 2006
39. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F: In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. *Blood* 108:1135-44, 2006
40. Frasca L, Fedele G, Deaglio S, Capuano C, Palazzo R, Vaisitti T, Malavasi F, Ausiello CM: CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. *Blood* 107:2392-9, 2006
41. Malavasi F, Deaglio S, Ferrero E, Funaro A, Sancho J, Ausiello CM, Ortolan E, Vaisitti T, Zubiaur M, Fedele G, Aydin S, Tibaldi EV, Durelli I, Lusso R, Cozno F, Horenstein AL: CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. *Mol Med* 12:334-41, 2006
42. Morabito F, Damle RN, Deaglio S, Keating M, Ferrarini M, Chiorazzi N: The CD38 ectoenzyme family: advances in basic science and clinical practice. *Mol Med* 12:342-4, 2006
43. Calzolari A, Oliviero I, Deaglio S, Mariani G, Biffoni M, Sposi NM, Malavasi F, Peschle C, Testa U: Transferrin receptor 2 is frequently expressed in human cancer cell lines. *Blood Cells Mol Dis* 39:82-91, 2007
44. D'Arena G, Tarnani M, Rumi C, Vaisitti T, Aydin S, De Filippi R, Perrone F, Pinto A, Chiusolo P, Deaglio S, Malavasi F, Laurenti L: Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. *Am J Hematol* 82:787-91, 2007
45. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enyoloji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC: Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med* 204:1257-65, 2007
46. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, Omede P, Scatolini M, Jaksic O, Chiorino G, Efremov D, Malavasi F: CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. *Blood* 110:4012-21, 2007
47. Deaglio S, Vaisitti T, Billington R, Bergui L, Omede P, Genazzani AA, Malavasi F: CD38/CD19: a lipid raft-dependent signaling complex in human B cells. *Blood* 109:5390-8, 2007
48. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC: CD39 and control of cellular immune responses. *Purinergic Signal* 3:171-80, 2007
49. Willimott S, Baou M, Huf S, Deaglio S, Wagner SD: Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. *Haematologica* 92:1359-66, 2007
50. Aydin S, Rossi D, Bergui L, D'Arena G, Ferrero E, Bonello L, Omede P, Novero D, Morabito F, Carbone A, Gaidano G, Malavasi F, Deaglio S: CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? *Blood* 111:5646-53, 2008

51. Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F: CD38 at the junction between prognostic marker and therapeutic target. *Trends Mol Med* 14:210-8, 2008
52. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T, Aydin S: Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. *Physiol Rev* 88:841-86, 2008
53. Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A: Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. *Br J Pharmacol* 153 Suppl 1:S457-64, 2008
54. Calzolari A, Deaglio S, Maldi E, Cassoni P, Malavasi F, Testa U: Tfr2 expression in human colon carcinomas. *Blood Cells Mol Dis* 43:243-9, 2009
55. Calzolari A, Finisguerra V, Oliviero I, Deaglio S, Mariani G, Malavasi F, Testa U: Regulation of transferrin receptor 2 in human cancer cell lines. *Blood Cells Mol Dis* 42:5-13, 2009
56. Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bomben R, Marasca R, Deaglio S, Laurenti L, Efremov DG, Gaidano G, Del Poeta G, Gattei V: Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. *J Transl Med* 7:76, 2009
57. De Martino L, D'Arena G, Minervini MM, Deaglio S, Fusco BM, Cascavilla N, De Feo V: Verbena officinalis essential oil and its component citral as apoptotic-inducing agent in chronic lymphocytic leukemia. *Int J Immunopathol Pharmacol* 22:1097-104, 2009
58. Deaglio S, Malavasi F: Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. *Haematologica* 94:752-6, 2009
59. Horenstein AL, Sizzano F, Lusso R, Besso FG, Ferrero E, Deaglio S, Corno F, Malavasi F: CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. *Mol Med* 15:76-84, 2009
60. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G: Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. *Clin Cancer Res* 15:4415-22, 2009
61. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, Bossi F, Lorenzon D, Degan M, Rossi FM, Rossi D, Bulian P, Franco V, Del Poeta G, Deaglio S, Gaidano G, Tedesco F, Malavasi F, Gattei V: CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. *Cancer Res* 69:40019, 2009
62. Calzolari A, Larocca LM, Deaglio S, Finisguerra V, Boe A, Raggi C, Ricci-Vitani L, Pierconti F, Malavasi F, De Maria R, Testa U, Pallini R: Transferrin receptor 2 is frequently and highly expressed in glioblastomas. *Transl Oncol* 3:123-34, 2010
63. D'Arena G, Capalbo S, Laurenti L, Del Poeta G, Nunziata G, Deaglio S, Spinosa G, Tarnani M, De Padua L, Califano C, Ferrara F, Cascavilla N: Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. *Eur J Haematol* 85:502-7, 2010

64. Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, D'Arena G, Chiorino G, Malavasi F: CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. *Mol Med* 16:87-91, 2010
65. Deaglio S, Vaisitti T, Zucchetto A, Gattei V, Malavasi F: CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. *Semin Cancer Biol* 20:416-23, 2010
66. Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, McRae JL, Winterhalter A, Doherty G, Deaglio S, Koulmanda M, Gao W, Robson SC, Strom TB: Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. *Am J Transplant* 10:2410-20, 2010
67. Malavasi F, Deaglio S, Zaccarello G, Horenstein AL, Chillemi A, Audrito V, Serra S, Gandione M, Zitella A, Tizzani A: The hidden life of NAD⁺-consuming ectoenzymes in the endocrine system. *J Mol Endocrinol* 45:183-91, 2010
68. Pearce L, Morgan L, Lin TT, Hewamana S, Matthews RJ, Deaglio S, Rowntree C, Fegan C, Pepper C, Brennan P: Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. *Haematologica* 95:514-7, 2010
69. Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C, Gaidano G, Malavasi F, Deaglio S: CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. *Leukemia* 24:958-69, 2010
70. Zucchetto A, Tripodo C, Benedetti D, Deaglio S, Gaidano G, Del Poeta G, Gattei V: Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells. *Br J Haematol* 150:111-3, 2010
71. Audrito V, Vaisitti T, Rossi D, Gottardi D, D'Arena G, Laurenti L, Gaidano G, Malavasi F, Deaglio S: Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. *Cancer Res* 71:4473-83, 2011
72. Bulian P, Tarnani M, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, Deaglio S, D'Arena G, Efremov D, Marasca R, Lauria F, Gattei V, Gaidano G, Laurenti L: Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. *Hematol Oncol* 29:919, 2011
73. Crowther-Swanepoel D, Di Bernardo MC, Jamroziak K, Karabon L, Frydecka I, Deaglio S, D'Arena G, Rossi D, Gaidano G, Olver B, Lloyd A, Broderick P, Laurenti L, Szemraj-Rogucka Z, Robak T, Catovsky D, Houlston RS: Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. *Br J Haematol* 154:229-33, 2011
74. D'Arena G, Deaglio S, Laurenti L, De Martino L, De Feo V, Fusco BM, Carella AM, Cascavilla N, Musto P: Targeting regulatory T cells for anticancer therapy. *Mini Rev Med Chem* 11:480-5, 2011
75. D'Arena G, Laurenti L, Minervini MM, Deaglio S, Bonello L, De Martino L, De Padua L, Savino L, Tarnani M, De Feo V, Cascavilla N: Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. *Leuk Res* 35:363-8, 2011
76. D'Arena G, Rossi G, Minervini MM, Savino L, D'Auria F, Laurenti L, Del Principe MI, Deaglio S, Biagi A, De Martino L, De Feo V, Statuto T, Musto P, Del Poeta G: Circulating regulatory T cells in clinical monoclonal B-cell lymphocytosis. *Int J Immunopathol Pharmacol* 24:915-23, 2011

77. Deaglio S, Robson SC: Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. *Adv Pharmacol* 61:301-32, 2011
78. Deaglio S, Vaisitti T, Serra S, Audrito V, Bologna C, D'Arena G, Laurenti L, Gottardi D, Malavasi F: CD38 in chronic lymphocytic leukemia: from bench to bedside? *Mini Rev Med Chem* 11:503-7, 2011
79. Ferretti E, Bertolotto M, Deaglio S, Tripodo C, Ribatti D, Audrito V, Blengio F, Matis S, Zupo S, Rossi D, Ottonello L, Gaidano G, Malavasi F, Pistoia V, Corcione A: A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. *Leukemia* 25:1268-77, 2011
80. Kunzli BM, Berberat PO, Dwyer K, Deaglio S, Csizmadia E, Cowan P, d'Apice A, Moore G, Enyoloji K, Friess H, Robson SC: Variable impact of CD39 in experimental murine colitis. *Dig Dis Sci* 56:1393-403, 2011
81. Laurenti L, De Padua L, D'Arena G, Vannata B, Innocenti I, Tarnani M, Deaglio S, Sica S, Efremov DG, Leone G: New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia. *Mini Rev Med Chem* 11:508-18, 2011
82. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N: CD38 and chronic lymphocytic leukemia: a decade later. *Blood* 118:3470-8, 2011
83. Pezzolo A, Parodi F, Marimpietri D, Raffaghello L, Cocco C, Pistorio A, Mosconi M, Gambini C, Cilli M, Deaglio S, Malavasi F, Pistoia V: Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. *Cell Res* 21:1470-86, 2011
84. Rasi S, Spina V, Brusca A, Vaisitti T, Tripodo C, Forconi F, De Paoli L, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D: A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. *Br J Haematol* 152:284-94, 2011
85. Rossi D, Brusca A, Spina V, Rasi S, Khiabani H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Foa R, Dalla-Favera R, Gaidano G: Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. *Blood* 118:6904-8, 2011
86. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Brusca A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foa R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G: Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. *Blood* 118:4930-4, 2011
87. Saborit-Villarroya I, Vaisitti T, Rossi D, D'Arena G, Gaidano G, Malavasi F, Deaglio S: E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. *Leukemia* 25:479-88, 2011
88. Sandini S, La Valle R, Deaglio S, Malavasi F, Cassone A, De Bernardis F: A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of *Candida albicans* as a mucosal anticandidal vaccine. *FEMS Immunol Med Microbiol* 62:215-24, 2011
89. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami G, Robson SC, Gaidano G, Malavasi F, Deaglio S: CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. *Blood* 118:6141-52, 2011

90. Vaisitti T, Audrito V, Serra S, Bologna C, Brusa D, Malavasi F, Deaglio S: NAD⁺-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model. *FEBS Lett* 585:151420, 2011
91. D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, Del Principe MI, Statuto T, Pietrantuono G, Guariglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P: A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. *Am J Hematol* 87:628-31, 2012
92. D'Arena G, Gemei M, Luciano L, D'Auria F, Deaglio S, Statuto T, Bianchino G, Grieco V, Mansueto G, Guariglia R, Pietrantuono G, Martorelli MC, Villani O, Del Vecchio L, Musto P: Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? *J Clin Oncol* 30:e327-30, 2012
93. D'Arena G, Rossi G, Vannata B, Deaglio S, Mansueto G, D'Auria F, Statuto T, Simeon V, De Martino L, Marandino A, Del Poeta G, De Feo V, Musto P: Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases. *Mediterr J Hematol Infect Dis* 4:e2012053, 2012
94. Dal Bo M, Bomben R, Zucchetto A, Del Poeta G, Gaidano G, Deaglio S, Efremov DG, Gattei V: Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy. *Curr Pharm Des* 18:3323-34, 2012
95. Isoardo G, Morra I, Chiarle G, Audrito V, Deaglio S, Melcarne A, Junemann C, Naddeo M, Cogoni M, Valentini MC, Limberti A, Faccani F, Malavasi F, Faccani G: Different aquaporin-4 expression in glioblastoma multiforme patients with and without seizures. *Mol Med* 18:1147-51, 2012
96. Maffei R, Fiorcari S, Bulgarelli J, Martinelli S, Castelli I, Deaglio S, Debbia G, Fontana M, Coluccio V, Bonacorsi G, Zucchini P, Narni F, Torelli G, Luppi M, Marasca R: Physical contact with endothelial cells through beta1- and beta2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. *Haematologica* 97:952-60, 2012
97. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A, Spina V, Deambrogi C, Marinelli M, Fama R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foa R, Gaidano G: Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. *Blood* 119:2854-62, 2012
98. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Fama R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foa R, Gaidano G: Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. *Blood* 119:521-9, 2012
99. Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Fama R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbo F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foa R, . . . Gaidano G: The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. *J Exp Med* 209:1537-51, 2012
100. Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, Bomben R, Dal Bo M, Del Principe MI, Gorgone A, Pozzato G, Gaidano G, Del Poeta G, Malavasi F, Deaglio S, Gattei V: The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. *Leukemia* 26:1301-12, 2012

101. Audrito V, Vaisitti T, Serra S, Bologna C, Brusa D, Malavasi F, Deaglio S: Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. *Cancer Lett* 328:27-35, 2013
102. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S: The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. *Haematologica* 98:953-63, 2013
103. D'Arena G, Simeon V, De Martino L, Statuto T, D'Auria F, Volpe S, Deaglio S, Maidecchi A, Mattoli L, Mercati V, Musto P, De Feo V: Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia. *Int J Immunopathol Pharmacol* 26:117-25, 2013
104. Longhi MS, Robson SC, Bernstein SH, Serra S, Deaglio S: Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. *J Mol Med (Berl)* 91:165-72, 2013
105. Maffei R, Bulgarelli J, Fiorcari S, Bertoncetti L, Martinelli S, Guarnotta C, Castelli I, Deaglio S, Debbia G, De Biasi S, Bonacorsi G, Zucchini P, Narni F, Tripodo C, Luppi M, Cossarizza A, Marasca R: The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. *Haematologica* 98:1115-23, 2013
106. Sava GP, Speedy HE, Di Bernardo MC, Deaglio S, Karabon L, Frydecka I, Woszczyk D, Rossi D, Gaidano G, Mansouri L, Smedby KE, Juliusson G, Rosenquist R, Catovsky D, Houlston RS: rs2072135, a lowpenetrance variant for chronic lymphocytic leukaemia? *Br J Haematol* 162:221-8, 2013
107. Vaisitti T, Audrito V, Serra S, Bologna C, Arruga F, Brusa D, Buonincontri R, Gizdic B, Deaglio S: Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia. *Curr Top Med Chem* 13:2955-64, 2013
108. Vaisitti T, Serra S, Pepper C, Rossi D, Laurenti L, Gaidano G, Malavasi F, Deaglio S: CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. *Leukemia* 27:1177-81, 2013
109. Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M, Laurenti L, D'Arena G, Jaksic O, Inghirami G, Rossi D, Gaidano G, Deaglio S: Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. *Leukemia* 28:1060-70, 2014
110. D'Arena G, Calapai G, Deaglio S: Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. *Expert Opin Ther Pat* 24:821-8, 2014
111. D'Arena G, Laurenti L, Coscia M, Cortelezzi A, Chiarenza A, Pozzato G, Vigliotti ML, Nunziata G, Fragasso A, Villa MR, Grossi A, Selleri C, Deaglio S, La Sala A, Del Poeta G, Simeon V, Aliberti L, De Martino L, Giudice A, Musto P, De Feo V: Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. *Leuk Lymphoma* 55:841-7, 2014
112. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, Mandala M: PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. *Ann Oncol* 25:2433-2442, 2014
113. Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D'Arena G, Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F, Deaglio S: HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. *Haematologica* 99:888-96, 2014

114. Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Garcia JG, Wolberger C, Raffaelli N, Deaglio S: Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. *Blood* 125:111-23, 2015
115. Fiorcari S, Martinelli S, Bulgarelli J, Audrito V, Zucchini P, Colaci E, Potenza L, Narni F, Luppi M, Deaglio S, Marasca R, Maffei R: Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. *Haematologica* 100:253-62, 2015
116. Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M: The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. *Ann Oncol* 26:1980-1987, 2015
117. Piva R, Deaglio S, Fama R, Buonincontri R, Scarfo I, Brusca A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacchi E, Bertoni F, Pileri SA, Foa R, Inghirami G, Gaidano G, Rossi D: The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. *Leukemia* 29:503-7, 2015
118. Sava GP, Speedy HE, Di Bernardo MC, Dyer MJ, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, Jayne S, Majid A, Wang Y, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS: Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. *Leukemia* 29:748-51, 2015
119. Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzone S, Deaglio S: The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. *Leukemia* 29:356-68, 2015
120. Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, Pagnani A, Coscia M, D'Arena G, Mereu E, Piva R, Furman RR, Rossi D, Gaidano G, Terhorst C, Deaglio S: SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. *J Clin Invest* 126:181-94, 2016
121. Buondonno I, Gazzano E, Jean SR, Audrito V, Kopecka J, Fanelli M, Salaroglio IC, Costamagna C, Roato I, Mungo E, Hattinger CM, Deaglio S, Kelley SO, Serra M, Riganti C: Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. *Mol Cancer Ther* 15:2640-2652, 2016
122. Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca R: Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. *Oncotarget* 7:65968-65981, 2016
123. Orso F, Quirico L, Virga F, Penna E, Dettori D, Cimino D, Coppo R, Grassi E, Elia AR, Brusa D, Deaglio S, Brizzi MF, Stadler MB, Provero P, Caselle M, Taverna D: miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer. *Cancer Res* 76:5151-62, 2016
124. Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, Benedetti D, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Deaglio S, Gattei V, Dal Bo M: NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. *Leukemia* 30:182-9, 2016

125. Salaro E, Rambaldi A, Falzoni S, Amoroso FS, Franceschini A, Sarti AC, Bonora M, Cavazzini F, Rigolin GM, Ciccone M, Audrito V, Deaglio S, Pelegrin P, Pinton P, Cuneo A, Di Virgilio F: Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death. *Sci Rep* 6:26280, 2016
126. Scarfo I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, Circosta P, Abate F, Barreca A, Novero D, Mathew S, Rinaldi A, Tiacci E, Serra S, Deaglio S, Neri A, Falini B, Rabadan R, Bertoni F, Inghirami G, Piva R, European TCLSG: Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. *Blood* 127:221-32, 2016
127. Serra S, Deaglio S: HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells. *J Vis Exp*, 2016
128. Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, Arruga F, Brusa D, Coscia M, Jaksic O, Inghirami G, Rossi D, Furman RR, Robson SC, Gaidano G, Chiorazzi N, Deaglio S: Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. *Blood Adv* 1:47-61, 2016
129. Spina V, Khiabani H, Messina M, Monti S, Cascione L, Brusca A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbo F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foa R, Rabadan R, Gaidano G, Rossi D: The genetics of nodal marginal zone lymphoma. *Blood* 128:1362-73, 2016
130. Arruga F, Gizdic B, Bologna C, Cignetto S, Buonincontri R, Serra S, Vaisitti T, Gizzi K, Vitale N, Garaffo G, Mereu E, Diop F, Neri F, Incarnato D, Coscia M, Allan J, Piva R, Oliviero S, Furman RR, Rossi D, Gaidano G, Deaglio S: Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. *Leukemia* 31:1882-1893, 2017
131. Audrito V, Serra S, Stingi A, Orso F, Gaudino F, Bologna C, Neri F, Garaffo G, Nassini R, Baroni G, Rulli E, Massi D, Oliviero S, Piva R, Taverna D, Mandala M, Deaglio S: PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. *Oncotarget* 8:15894-15911, 2017
132. D'Arena G, Vitale C, Perbellini O, Coscia M, La Rocca F, Ruggieri V, Visco C, Di Minno NMD, Innocenti I, Pizza V, Deaglio S, Di Minno G, Giudice A, Calapai G, Musto P, Laurenti L, Iorio EL: Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. *Eur J Haematol* 99:306-314, 2017
133. De Luca L, D'Arena G, Simeon V, Trino S, Laurenzana I, Caivano A, La Rocca F, Villani O, Mansueto G, Deaglio S, Innocenti I, Laurenti L, Molica S, Pietrantuono G, De Stradis A, Del Vecchio L, Musto P: Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. *Leuk Lymphoma* 58:1424-1432, 2017
134. Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, Castella B, Peola S, Foglietta M, Drandi D, Omede P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M, Coscia M: Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. *Oncotarget* 8:3274-3288, 2017
135. Maffei R, Fiorcari S, Vaisitti T, Martinelli S, Benatti S, Debbia G, Rossi D, Zucchini P, Potenza L, Luppi M, Gaidano G, Deaglio S, Marasca R: Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. *Oncotarget* 8:90013-90027, 2017

136. Vaisitti T, Gaudino F, Ouk S, Moscvin M, Vitale N, Serra S, Arruga F, Zakrzewski JL, Liou HC, Allan JN, Furman RR, Deaglio S: Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-kappaB inhibitor. *Haematologica* 102:1878-1889, 2017
137. Arruga F, Deaglio S: Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia. *Handb Exp Pharmacol* 249:203-229, 2018
138. Arruga F, Vaisitti T, Deaglio S: The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies. *Front Oncol* 8:550, 2018
139. Audrito V, Manago A, La Vecchia S, Zamporlini F, Vitale N, Baroni G, Cignetto S, Serra S, Bologna C, Stingi A, Arruga F, Vaisitti T, Massi D, Mandala M, Raffaelli N, Deaglio S: Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. *J Natl Cancer Inst* 110, 2018
140. Audrito V, Manago A, Zamporlini F, Rulli E, Gaudino F, Madonna G, D'Atri S, Antonini Cappellini GC, Ascierto PA, Massi D, Raffaelli N, Mandala M, Deaglio S: Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. *Oncotarget* 9:18997-19005, 2018
141. Bologna C, Deaglio S: Linking SLAMF1 to autophagy and sensitivity to therapy in chronic lymphocytic leukemia. *Mol Cell Oncol* 5:e1143077, 2018
142. Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foa R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G: Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. *Oncoimmunology* 7:e1341032, 2018
143. D'Arena G, Vitale C, Rossi G, Coscia M, Omede P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L: CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. *Hematol Oncol*, 2018
144. Vaisitti T, Arruga F, Deaglio S: Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche? *Int J Mol Sci* 19, 2018
145. Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamo A, Tam W, Chadburn A, Furman RR, Deaglio S: Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. *Cancer Res* 78:3413-3420, 2018
146. Audrito V, Manago A, Gaudino F, Sorci L, Messina VG, Raffaelli N, Deaglio S: NAD Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer. *Front Immunol* 10:1720, 2019
147. Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omede P, Todoerti K, Cascione L, Audrito V, Riccio A, Rossi A, Bertoni F, Deaglio S, Neri A, Palumbo A, Piva R: IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. *Blood* 133:156-167, 2019
148. Fishman CE, Mohebasab M, van Setten J, Zanoni F, Wang C, Deaglio S, Amoroso A, Callans L, van Gelder T, Lee S, Kiryluk K, Lanktree MB, Keating BJ: Genome-Wide Study Updates in the International Genetics and Translational Research in Transplantation Network (iGeneTRAIN). *Front Genet* 10:1084, 2019

149. Gaudino F, Manfredonia I, Manago A, Audrito V, Raffaelli N, Vaisitti T, Deaglio S: Subcellular Characterization of Nicotinamide Adenine Dinucleotide Biosynthesis in Metastatic Melanoma by Using Organelle-Specific Biosensors. *Antioxid Redox Signal* 31:1150-1165, 2019
150. Manago A, Audrito V, Mazzola F, Sorci L, Gaudino F, Gizzi K, Vitale N, Incarnato D, Minazzato G, Ianniello A, Varriale A, D'Auria S, Mengozzi G, Politano G, Oliviero S, Raffaelli N, Deaglio S: Extracellular nicotinate phosphoribosyltransferase binds Toll like receptor 4 and mediates inflammation. *Nat Commun* 10:4116, 2019
151. Morandi E, Cereda M, Incarnato D, Parlato C, Basile G, Anselmi F, Lauria A, Simon LM, Laurence Polignano I, Arruga F, Deaglio S, Tirtei E, Fagioli F, Oliviero S: HaTSPiL: A modular pipeline for highthroughput sequencing data analysis. *PLoS One* 14:e0222512, 2019
152. Steers NJ, Li Y, Drace Z, D'Addario JA, Fischman C, Liu L, Xu K, Na YJ, Neugut YD, Zhang JY, Sterken R, Balderes O, Bradbury D, Ozturk N, Ozay F, Goswami S, Mehl K, Wold J, Jelloul FZ, Rohanizadegan M, Gillies CE, Vasilescu EM, Vlad G, Ko YA, Mohan S, Radhakrishnan J, Cohen DJ, Ratner LE, Scolari F, Susztak K, Sampson MG, Deaglio S, Caliskan Y, Barasch J, Courtney AE, Maxwell AP, . . . Kiryluk K: Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection. *N Engl J Med* 380:1918-1928, 2019
153. Vaisitti T, Arruga F, Guerra G, Deaglio S: Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets. *Front Immunol* 10:2301, 2019
154. Villanova T, Gesmundo I, Audrito V, Vitale N, Silvagno F, Musuraca C, Righi L, Libener R, Riganti C, Bironzo P, Deaglio S, Papotti M, Cai R, Sha W, Ghigo E, Schally AV, Granata R: Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. *Proc Natl Acad Sci U S A* 116:2226-2231, 2019
155. Arruga F, Bracciana V, Vitale N, Vaisitti T, Gizzi K, Yeomans A, Coscia M, D'Arena G, Gaidano G, Allan JN, Furman RR, Packham G, Forconi F, Deaglio S: Correction: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. *Leukemia* 34:1721, 2020
156. Arruga F, Bracciana V, Vitale N, Vaisitti T, Gizzi K, Yeomans A, Coscia M, D'Arena G, Gaidano G, Allan JN, Furman RR, Packham G, Forconi F, Deaglio S: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. *Leukemia* 34:462-477, 2020
157. Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S: Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. *Int J Mol Sci* 21, 2020
158. Audrito V, Manago A, Gaudino F, Deaglio S: Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). *Semin Cell Dev Biol* 98:192-201, 2020
159. Audrito V, Messina VG, Deaglio S: NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. *Front Oncol* 10:358, 2020
160. Audrito V, Messina VG, Moiso E, Vitale N, Arruga F, Brandimarte L, Gaudino F, Pellegrino E, Vaisitti T, Riganti C, Piva R, Deaglio S: NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. *Cancers (Basel)* 12, 2020

161. D'Arena G, De Feo V, Pietrantuono G, Seneca E, Mansueto G, Villani O, La Rocca F, D'Auria F, Statuto T, Valvano L, Arruga F, Deaglio S, Efremov DG, Sgambato A, Laurenti L: CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance. *Front Oncol* 10:584427, 2020
162. Deaglio S, Amoroso A, Rinaldi M, Boffini M: HLA typing in lung transplantation: does high resolution fit all? *Ann Transl Med* 8:45, 2020
163. Deaglio S, Hartmann TN: The Importance of Tumor-Host Interactions in Adult B-Cell Leukemias and Lymphomas. *Int J Mol Sci* 21, 2020
164. Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscazzin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambroggi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Giudice ID, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, . . . Rossi D: Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. *Haematologica* 105:448-456, 2020
165. Grolla AA, Miggiano R, Di Marino D, Bianchi M, Gori A, Orsomando G, Gaudino F, Galli U, Del Grosso E, Mazzola F, Angeletti C, Guarneri M, Torretta S, Calabro M, Boumya S, Fan X, Colombo G, Travelli C, Rocchio F, Aronica E, Wohlschlegel JA, Deaglio S, Rizzi M, Genazzani AA, Garavaglia S: A nicotinamide phosphoribosyltransferase-GAPDH interaction sustains the stress-induced NMN/NAD(+) salvage pathway in the nucleus. *J Biol Chem* 295:3635-3651, 2020
166. Lorenzato A, Magri A, Matafora V, Audrito V, Arcella P, Lazzari L, Montone M, Lamba S, Deaglio S, Siena S, Bertotti A, Trusolino L, Bachi A, Di Nicolantonio F, Bardelli A, Arena S: Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. *Cancers (Basel)* 12, 2020
167. Vaisitti T, Sorbini M, Callegari M, Kalantari S, Bracciana V, Arruga F, Vanzino SB, Rendine S, Togliatto G, Giachino D, Pelle A, Cocchi E, Benvenuta C, Baldovino S, Rollino C, Fenoglio R, Sciascia S, Tamagnone M, Vitale C, Calabrese G, Biancone L, Bussolino S, Savoldi S, Borzumati M, Cantaluppi V, Chiappero F, Ungari S, Peruzzi L, Roccatello D, Amoroso A, Deaglio S: Clinical exome sequencing is a powerful tool in the diagnostic flow of monogenic kidney diseases: an Italian experience. *J Nephrol*, 2020
168. Amoroso A, Magistrini P, Vespasiano F, Bella A, Bellino S, Puoti F, Alizzi S, Vaisitti T, Boros S, Grossi PA, Trapani S, Lombardini L, Pezzotti P, Deaglio S, Bruscaferro S, Cardillo M, Italian Network of Regional Transplant Coordinating C: HLA and ABO Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity. *Transplantation* 105:193-200, 2021
169. Arruga F, Serra S, Vitale N, Guerra G, Papait A, Baffour Gyau B, Tito F, Efremov D, Vaisitti T, Deaglio S: Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia. *Haematologica* 106:1343-1353, 2021
107. Audrito V, Messina VG, Brandimarte L, Deaglio S: The Extracellular NADome Modulates Immune Responses. *Front Immunol* 12:704779, 2021

171. Barutta F, Kimura S, Hase K, Bellini S, Corbetta B, Corbelli A, Fiordaliso F, Barreca A, Papotti MG, Ghiggeri GM, Salvidio G, Roccatello D, Audrito V, Deaglio S, Gambino R, Bruno S, Camussi G, Martini M, Hirsch E, Durazzo M, Ohno H, Gruden G: Protective Role of the M-Sec-Tunneling Nanotube System in Podocytes. *J Am Soc Nephrol* 32:1114-1130, 2021
172. Chakraborty S, Martines C, Porro F, Fortunati I, Bonato A, Dimishkovska M, Piazza S, Yadav BS, Innocenti I, Fazio R, Vaisitti T, Deaglio S, Zamo A, Dimovski AJ, Laurenti L, Efremov DG: B Cell Receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter Transformation. *Blood*, 2021
173. Fiorito V, Allocco AL, Petrillo S, Gazzano E, Torretta S, Marchi S, Destefanis F, Pacelli C, Audrito V, Provero P, Medico E, Chiabrando D, Porporato PE, Cancelliere C, Bardelli A, Trusolino L, Capitanio N, Deaglio S, Altruda F, Pinton P, Cardaci S, Riganti C, Tolosano E: The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation. *Cell Rep* 35:109252, 2021
174. Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, Laudanna C, Allan JN, Furman RR, Pachter JA, Deaglio S, Vaisitti T: Synergistic efficacy of the dual PI3K-delta/gamma inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. *Blood* 137:3378-3389, 2021
175. Migliorero M, Kalantari S, Bracciana V, Sorbini M, Arruga F, Peruzzi L, Biamino E, Amoroso A, Vaisitti T, Deaglio S: A novel COLEC10 mutation in a child with 3MC syndrome. *Eur J Med Genet* 64:104374, 2021
176. Sorbini M, Togliatto GM, Simonato E, Boffini M, Cappuccio M, Gambella A, Arruga F, Mora N, Marro M, Caorsi C, Mansouri M, Magistrini P, Delsedime L, Papotti MG, Amoroso A, Rinaldi M, Vaisitti T, Deaglio S: HLA-DRB1 mismatch-based identification of donor-derived cell free DNA (dd-cfDNA) as a marker of rejection in heart transplant recipients: A single-institution pilot study. *J Heart Lung Transplant* 40:794804, 2021
177. Vaisitti T, Arruga F, Vitale N, Lee TT, Ko M, Chadburn A, Braggio E, Di Napoli A, Iannello A, Allan JN, Miller LL, Lannutti BJ, Furman RR, Jessen KA, Deaglio S: ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. *Blood* 137:3365-3377, 2021
178. Vaisitti T, Peritore D, Magistrini P, Ricci A, Lombardini L, Gringeri E, Catalano S, Spada M, Sciveres M, Di Giorgio A, Limongelli G, Varrenti M, Gerosa G, Terzi A, Napoleone CP, Amodeo A, Ragni L, Strologo LD, Benetti E, Fontana I, Testa S, Peruzzi L, Mitrotti A, Abbate S, Comai G, Gotti E, Schiavon M, Boffini M, De Angelis D, Bertani A, Pinelli D, Torre M, Poggi C, Deaglio S, Cardillo M, Amoroso A, Italian Pediatric Transplant C: The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy. *Orphanet J Rare Dis* 16:374, 2021
179. Vaisitti T, Vitale C, Iannello A, Brandimarte L, Micillo M, Papotti MG, Di Napoli A, C. O, M. K, A. P, Deaglio S: Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome. *Blood* 138:791, 2021
180. Wang L, Londono LM, Cowell J, Saatci O, Aras M, Ersan PG, Serra S, Pei H, Clift R, Zhao Q, Phan KB, Huang L, LaBarre MJ, Li X, Shepard HM, Deaglio S, Linden J, Thanos CD, Sahin O, Cekic C: Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. *Cancer Res* 81:3319-3332, 2021
181. Audrito V, Moiso E, Ugolini F, Messana VG, Brandimarte L, Manfredonia I, Bianchi S, De Logu F, Nassini R, Szumera-Cieckiewicz A, Taverna D, Massi D, Deaglio S: Tumors carrying BRAF-mutations

- overexpress NAMPT that is genetically amplified and possesses oncogenic properties. *J Transl Med* 20:118, 2022
- 182 Deaglio S, Vaisitti T: A new taxonomy for splenic marginal zone lymphoma. *Blood* 139:644645, 2022
- 183 Kalantari S, Brezzi B, Bracciana V, Barreca A, Nozza P, Vaisitti T, Amoroso A, Deaglio S, Manganaro M, Porta F, Spada M: Adult-onset CblC deficiency: a challenging diagnosis involving different adult clinical specialists. *Orphanet J Rare Dis* 17:33, 2022
- 184 Pinon M, Pizzol A, Chiado C, David E, Chiusa L, Dell'Olio D, Isolato G, Amoroso A, Deaglio S, Catalano S, Tandoi F, Romagnoli R, Calvo PL: Evaluation of Graft Fibrosis, Inflammation, and Donor-specific Antibodies at Protocol Liver Biopsies in Pediatric Liver Transplant Patients: A Single-center Experience. *Transplantation* 106:85-95, 2022
- 185 Iannello A, Deaglio S, Vaisitti T. Novel approaches for the treatment of patients with Richter's syndrome. *Curr Treat Options Oncol.* 23(4):526-542, 2022
186. Gasparrini M, Mazzola F, Cuccioloni M, Sorci L, Audrito V, Zamporlini F, Fortunato C, Amici A, Cianci M, Deaglio S, Angeletti M, Raffaelli N: Molecular insights into the interaction between human nicotinamide phosphoribosyltransferase and Toll-like receptor 4. *J Biol Chem* 298:101669, 2022
187. Gesmundo I, Pedrolli F, Vitale N, Bertoldo A, Orlando G, Banfi D, Granato G, Kasarla R, Balzola F, Deaglio S, Cai R, Sha W, Papotti M, Ghigo E, Schally AV, Granata R: Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma. *Int J Mol Sci* 23, 2022
188. Grosso A, Yannuzzi LA, Tsang SH, Ceruti P, Sarraf D, Zamir E, Kaminska K, Quinodoz M, Amoroso A, Deaglio S, Francis JH, Fioretto M, Rivolta C, Calzetti G: A Unique Presentation of Bilateral Chorioretinal Atrophy. *Asia Pac J Ophthalmol (Phila)*, 2022
189. D'Arena G, Sgambato A, Volpe S, Coppola G, Amodeo R, Tirino V, D'Auria F, Statuto T, Valvano L, Pietrantuono G, Deaglio S, Efremov D, Laurenti L, Aiello A: Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand? *Hematol Oncol* 40:835842, 2022
190. Deaglio S: Glutamine and CLL: ready for prime time? *Blood* 140:528-529, 2022
191. Mangolini M, Maiques-Diaz A, Charalampopoulou S, Gerhard-Hartmann E, Bloehdorn J, Moore A, Giachetti G, Lu J, Roamio Franklin VN, Chilamakuri CSR, Moutsopoulos I, Rosenwald A, Stilgenbauer S, Zenz T, Mohorianu I, D'Santos C, Deaglio S, Hodson DJ, Martin-Subero JI, Ringshausen I: Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape. *Nat Commun* 13:6220, 2022
192. Marchionni L, Lobo FP, Kostadinov R, Serra A, Besso FG, Deaglio S, Stratta P, Berrino M, Zanettini C, Imada EL, Omar MN, Gaidano G, Bruno B, Saglio G, Amoroso A: Donor-derived acute myeloid leukemia in solid organ transplantation. *Am J Transplant* 22:3111-3119, 2022
193. Martines C, Chakraborty S, Vujovikj M, Gobessi S, Vaisitti T, Deaglio S, Laurenti L, Dimovski AJ, Efremov DG: Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo. *Blood* 140:2335-2347, 2022
194. Sorbini M, Togliatto G, Mioli F, Simonato E, Marro M, Cappuccio M, Arruga F, Caorsi C, Mansouri M, Magistrini P, Gambella A, Delsedime L, Papotti MG, Solidoro P, Albera C, Boffini M, Rinaldi M,

Amoroso A, Vaisitti T, Deaglio S: Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients. *Transpl Int* 35:10546, 2022

195. Vaisitti T, Vitale N, Micillo M, Brandimarte L, Iannello A, Papotti MG, Jaksic O, Lopez G, Di Napoli A, Cutrin JC, Orlik C, Kulke M, Pahl A, Deaglio S: Anti-CD37 alpha-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome. *Blood* 140:1565-1569, 2022
196. Arruga, F., Rubin, M., Papazoglou, D., Iannello, A., Ioannou, N., Moia, R., Rossi, D., Gaidano, G., Coscia, M., Laurenti, L., et al. (2023). The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy. *Haematologica* 108, 2101-2115. 10.3324/haematol.2022.282177.
197. Bertinetto, F.E., Magistrini, P., Mazzola, G.A., Costa, C., Elena, G., Alizzi, S., Scozzari, G., Migliore, E., Galassi, C., Ciccone, G., et al. (2023). The humoral and cellular response to mRNA SARS-CoV-2 vaccine is influenced by HLA polymorphisms. *HLA*. 10.1111/tan.15049.
198. De Stefano, N., Calleri, A., Faini, A.C., Navarro-Tableros, V., Martini, S., Deaglio, S., Patrono, D., and Romagnoli, R. (2023). Extracellular Vesicles in Liver Transplantation: Current Evidence and Future Challenges. *Int J Mol Sci* 24. 10.3390/ijms241713547.
199. Deaglio, S. (2023). Chemoresistance pathways in DLBCL. *Blood* 142, 943-944. 10.1182/blood.2023021142.
200. Deaglio, S., and Ringshausen, I. (2023). Editorial: Tumour microenvironment heterogeneity in hematological malignancies. *Front Oncol* 13, 1295996. 10.3389/fonc.2023.1295996.
201. Grosso, A., Yannuzzi, L.A., Tsang, S.H., Ceruti, P., Sarraf, D., Zamir, E., Kaminska, K., Quinodoz, M., Amoroso, A., Deaglio, S., et al. (2023). A Unique Presentation of Bilateral Chorioretinal Atrophy. *Asia Pac J Ophthalmol (Phila)* 12, 500-501. 10.1097/APO.0000000000000563.
202. Gyau, B.B., and Deaglio, S. (2023). A(2A) receptor signaling drives cisplatin-mediated hippocampal neurotoxicity and cognitive defects in mice. *Purinergic Signal*. 10.1007/s11302-023-09919-0.
203. Peruzzi, L., and Deaglio, S. (2023). Rejection markers in kidney transplantation: do new technologies help children? *Pediatr Nephrol* 38, 2939-2955. 10.1007/s00467-022-05872-z.
204. Saglia, C., Bracciana, V., Trotta, L., Mioli, F., Faini, A.C., Brach Del Prever, G.M., Kalantari, S., Luca, M., Romeo, C.M., Scolari, C., et al. (2023). Relevance of next generation sequencing (NGS) data reanalysis in the diagnosis of monogenic diseases leading to organ failure. *BMC Med Genomics* 16, 303. 10.1186/s12920-023-01747-w.
205. Ten Hacken, E., Sewastianik, T., Yin, S., Hoffmann, G.B., Gruber, M., Clement, K., Penter, L., Redd, R.A., Ruthen, N., Hergalant, S., et al. (2023). In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. *Blood Cancer Discov* 4, 150-169. 10.1158/2643-3230.BCD-22-0082.
206. Vaisitti, T., Bracciana, V., Faini, A.C., Brach Del Prever, G.M., Callegari, M., Kalantari, S., Mioli, F., Romeo, C.M., Luca, M., Camilla, R., et al. (2023). The role of genetic testing in the diagnostic workflow of pediatric patients with kidney diseases: the experience of a single institution. *Hum Genomics* 17, 10. 10.1186/s40246-023-00456-w.
207. Vitale, C., Griggio, V., Todaro, M., Riganti, C., Jones, R., Boccillato, E., Perutelli, F., Arruga, F., Vaisitti, T., Efremov, D.G., et al. (2023). Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia. *Sci Rep* 13, 16950. 10.1038/s41598-02344039-0.
208. Caldo, D., Massarini, E., Rucci, M., Deaglio, S., and Ferracini, R. (2024). Epigenetics in Knee Osteoarthritis: A 2020-2023 Update Systematic Review. *Life (Basel)* 14. 10.3390/life14020269.
209. Fasci, A., and Deaglio, S. (2024). Role of CD73 and the purinergic signaling pathway in the pathogenesis of fusion-negative rhabdomyosarcoma. *Purinergic Signal*. 10.1007/s11302-02410013-2.

210. Messana, V.G., Fasci, A., Vitale, N., Micillo, M., Rovere, M., Pesce, N.A., Martines, C., Efremov, D.G., Vaisitti, T., and Deaglio, S. (2024). A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome. *Blood Adv* 8, 1920-1933. 10.1182/bloodadvances.2023011690.
211. Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalue, L., et al. (2024). RICTOR/mTORC2 downregulation in BRAF(V600E) melanoma cells promotes resistance to BRAF/MEK inhibition. *Mol Cancer* 23, 105. 10.1186/s12943-024-02010-1.
212. Rigo, A., Vaisitti, T., Laudanna, C., Terrabuio, E., Micillo, M., Frusteri, C., D'Ulivo, B., Merigo, F., Sbarbati, A., Mellert, K., et al. (2024). Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome. *Cell Death Dis* 15, 323. 10.1038/s41419-024-06707-5.
213. Saglia, C., Arruga, F., Scolari, C., Kalantari, S., Albanese, S., Bracciana, V., Corso Faini, A., Brach Del Prever, G., Luca, M., Romeo, C., et al. (2024). Functional evaluation of a novel nonsense variant of the calcium-sensing receptor gene leading to hypocalcemia. *Eur J Endocrinol* 190, 296-306. 10.1093/ejendo/lvae035.
214. Sorbini, M., Carradori, T., Togliatto, G.M., Vaisitti, T., and Deaglio, S. (2024). Technical Advances in Circulating Cell-Free DNA Detection and Analysis for Personalized Medicine in Patients' Care. *Biomolecules* 14. 10.3390/biom14040498.
215. Tanzi, A., Buono, L., Grange, C., Iampietro, C., Brossa, A., Arcolino, F.O., Arigoni, M., Calogero, R., Perin, L., Deaglio, S., et al. (2024). Urine-derived podocytes from steroid resistant nephrotic syndrome patients as a model for renal-progenitor derived extracellular vesicles effect and drug screening. *Res Sq*. 10.21203/rs.3.rs-3959549/v1.
216. Allesina A, Lavacca A, Fop F, Giraudi R, Giovinazzo G, Deaglio S, Caorsi C, Dolla C, Gallo E, Mella A, Biancone L: Significant Long-Term Prevention of High Sensitization After Kidney Allograft Failure by Maintaining Calcineurin Inhibitor-Based Immunosuppression. *Clin Transplant* 38:e15394, 2024

Torino, 19 novembre 2024

F.to Silvia Deaglio

Autorizzo il trattamento dei miei dati personali ai sensi della legge 675/96